Nixon Peabody
Pac Premier
You are here:  Home  >  Biotech  >  Current Article

Amgen stock climbs on cancer drug test news

By   /   Monday, June 3rd, 2019  /   Comments Off on Amgen stock climbs on cancer drug test news

    Print       Email
Story updated at 3 p.m. June 3: The first clinical results for new cancer treatments from Amgen injected a little energy into its stock June 3, which has hovered near 52-week lows for two weeks. Shares rose 3.4 percent for the day after the Thousand Oaks company announced Phase 1 data for AMG 510, a…


    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Henry Dubroff

Dubroff: After a decade ruled by tech, value stocks could make a comeback

Read More →